A Phase III clinical trial led by Neeraj Agarwal, MD, FASCO, senior director of clinical research at Huntsman Cancer ...

Compared to conventional imaging techniques, prostate specific membrane antigen (PSMA) PET imaging provides superior ...

ADT plus apalutamide before and after surgery significantly improved metastasis-free survi ...

Talazoparib plus enzalutamide reduces progression risk by 50% in men with DNA repair alter ...

The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...

A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...

Johnson & Johnson (J&J) has announced results from the final analysis of the phase 3 PROTEUS study showing that Erleada ...

Ceramides-lipid molecules in cells that affect many physiological functions including cell differentiation, migration, and ...

Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus hormone therapy (androgen deprivation ...

PSMA-PET has an important role in the accurate staging of recurrent prostate cancer. Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease ...

High-risk localized and locally advanced prostate cancer patients treated with apalutamide—a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone therapy before and ...

*Foster Sylvers, the former child star whose youthful voice and magnetic stage presence helped propel The Sylvers to national ...